Biohope presents the results of the BIOTRAIM study on the use of pretransplant Immunobiogram® at the World Transplant Congress 2025 and they are selected among the most relevant abstracts in kidney transplantation
Immunobiogram® is a test that measures in vitro the sensitivity (response) of each patient's immune system cells to immunosuppressive drugs, with the aim of facilitating the personalization of immunosuppressive therapy in patients with a kidney transplant.
Biohope, a biotechnology R&D company specialized in precision medicine and located in the Madrid Science Park, participated in the World Transplant Congress (WTC 2025) in San Francisco from 3 to 6 August 2025. The company presented two oral communications on the results of the BIOTRAIM study.
The BIOTRAIM study aimed to evaluate the ability of the Immunobiogram®, performed pre-transplant, to predict rejection in patients over a one-year follow-up period, in addition to the risk estimated by traditional clinical factors (such as the age and type of donor, the age of the recipient, the level of immunological incompatibility between both, and the existence of a previous transplant).
The results show that Immunobiogram® provides additional predictive information about the risk of rejection, beyond that offered by conventional clinical factors. This predictive capacity is observed not only in patients at high risk of rejection, but also in those at low or medium risk. According to these data, the sensitivity profile of patients to immunosuppressants, measured with the Immunobiogram®, should be considered as a relevant criterion for selecting the immunosuppressive therapy in any renal transplant candidate, regardless of their clinical risk.
The WTC 2025 has been the most important event of the year in the field of transplantation, as this edition integrated the ATC (American Transplant Association) congress, which was held separately in previous years. With the aim of addressing the issues that concern nephrologists around the world the most, Dr Ali reviewed the 1,550 abstracts submitted to the congress in the field of renal transplantation, making an initial selection of 50 and a final selection of 30. The abstract presented by Biohope, with the results of the BIOTRAIM study, was selected and its results were presented at the closing plenary session ('Reflection, Revelations and the Road Ahead'), in which the most relevant data from the congress are summarised.
The WTC congress represents a strategic opportunity for Biohope to raise awareness of its technology and the results of its clinical research studies among the international transplant community. It is a space for interaction with thought leaders and companies from around the world, as well as a forum for scientific updates in this field. Biohope aims to contribute innovatively to the advancement of personalisation and optimisation of immunosuppressive therapies in transplantation, and is preparing to enter the US market.